This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-22. Anything still debated is marked as such rather than presented as settled.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Nutritional yeast in particular is naturally low in fat and sodium and a source of protein and vitamins as well as other minerals and cofactors required for growth. Many brands of nutritional yeast and yeast extract spreads, though not all, are fortified with vitamin B12, which is produced separately by bacteria. In 1920, the Fleischmann Yeast Company began to promote yeast cakes in a "Yeast for Health" campaign. They initially emphasized yeast as a source of vitamins, good for skin and digestion. Their later advertising claimed a much broader range of health benefits, and was censured as misleading by the Federal Trade Commission. The fad for yeast cakes lasted until the late 1930s. Yeast cell walls are used as a source of dietary fiber. Specifically, the glucan part is marketed as "yeast β-glucan" and the mannan part is further processed into mannan-oligosaccharide (MOS).
DROME: Gln-Tyr-Met-Ser-Pro-Cys-His-Phe-Lys-Ile-Cys-Asn-Met-amide APIME: Thr-Met-Ile-Ser-Tyr-Met-Thr-Leu-Cys-His-Phe-Lys-Ile-Cys-Asn-Met-amide DAPPU: Asp-Ser-Tyr-Leu-Ser-Met-Cys-His-Phe-Lys-Leu-Cys-Asn-Leu-amide
==== Source 2007 ==== The Source 2007 branch represented a full upgrade of the Source engine for the release of The Orange Box. An artist-driven, threaded particle system replaced previously hard-coded effects for all of the games within. An in-process tools framework was created to support it, which also supported the initial builds of Source Filmmaker. In addition, the facial animation system was made hardware-accelerated on modern video cards for "feature film and broadcast television" quality. The release of The Orange Box on multiple platforms allowed for a large code refactoring, which let the Source engine take advantage of multiple CPU cores. However, support on the PC was experimental and unstable until the release of Left 4 Dead. Multiprocessor support was later backported to Team Fortress 2 and Day of Defeat: Source. Valve created the Xbox 360 release of The Orange Box in-house, and support for the console is fully integrated into the main engine codeline. It includes asset converters, cross-platform play and Xbox Live integration. The PlayStation 3 release was outsourced to Electronic Arts, and was plagued with issues throughout the process. Gabe Newell cited these issues when criticizing the console during the release of The Orange Box.
However, the degree of fractionation is not necessarily consistent between organisms, complicating the determination of paleosalinity with this method. There also appears to be a negative correlation between growth rate and fractionation in these coccolithophores. Further experiments on unicellular algae Eudorina unicocca and Volvox aureus show no effect of growth rate (controlled by nitrogen limitation) on fatty acid δD. However, sterols become more D-depleted as growth rate increases, in agreement with alkenone isotopic composition in coccolithophores. Overall, although there are some strong trends with lipid δD, the specific fractionations are compound-specific. As a result, any attempt to create a salinometer through δD measurements will necessarily be specific to a single compound type.
In the canaliculus, secreted hydrogen and chloride ions mix and are secreted into the lumen of the oxyntic gland. The highest concentration that gastric acid reaches in the stomach is 160 mM in the canaliculi. This is about 3 million times that of arterial blood, but almost exactly isotonic with other bodily fluids. The lowest pH of the secreted acid is 0.8, but the acid is diluted in the stomach lumen to a pH of between 1 and 3. There is a small continuous basal secretion of gastric acid between meals of usually less than 10 mEq/hour. There are three phases in the secretion of gastric acid which increase the secretion rate in order to digest a meal:
Sources: en.wikipedia.org
=== 1980s === 1980: introduces low-protein binding Durapore polyvinylidene fluoride membrane 1987: listed on the New York Stock Exchange 1987: achieves $500 million revenue 1988: opens membrane manufacturing plant in County Cork, Ireland
Field rations can be eaten at any temperature, but are preferably heated or cooked. However, as the use of cooking appliances or fire may be unavailable or tactically unwise, smokeless solid fuel and a portable stove are typically included in rations to heat meals. Hexamine fuel tablets have traditionally been preferred, though gelatinized ethanol is also sometimes used. Some modern field rations use a flameless ration heater instead of fuel tablets. NATO standardization states that, while main courses and entrées must be consumable without heating, main course components and hot beverages should be provided with a heater, with such items intended to be heated to a minimum temperature of 62 °C from an ambient temperature of 20 °C within 12 minutes.
=== Calibration === Continuous glucose monitoring systems do not always produce readings identical to those obtained through fingerstick blood glucose testing. Differences between CGM and fingerstick values are expected due to physiological and technical factors, including the lag time between glucose levels in interstitial fluid and those in capillary blood. While the Dexcom G7 has a reported MARD of approximately 8.2%, variations of up to 20% between CGM and fingerstick readings are considered within the normal accuracy range. These differences are particularly noticeable during periods of rapid glucose change, such as after meals, physical activity, or insulin administration. As a result, CGM readings are most reliable when glucose levels are stable, and discrepancies may occur during times of fluctuation. There is an option to calibrate using a blood glucose reading taken from another device such as a blood glucose meter that uses a fingerstick lancing device, but it is not mandatory on any currently available Dexcom CGMs. The "20 rule" (or 20/20 rule) is commonly used to assess the accuracy of the CGM. If the difference between the Dexcom G6 or G7 reading and the fingerstick blood glucose meter value is within 20% (or 20 mg/dL when glucose levels are under 80 mg/dL), the sensor is operating within its expected error margin. While CGM and meter readings may not match exactly, they should generally fall within this acceptable range, especially when glucose levels are stable.
The CCT then causes actin's sequential folding by forming bonds with its subunits rather than simply enclosing it in its cavity. This is why it possesses specific recognition areas in its apical β-domain. The first stage in the folding consists of the recognition of residues 245–249. Next, other determinants establish contact. Both actin and tubulin bind to CCT in open conformations in the absence of ATP. In actin's case, two subunits are bound during each conformational change, whereas for tubulin binding takes place with four subunits. Actin has specific binding sequences, which interact with the δ and β-CCT subunits or with δ-CCT and ε-CCT. After AMP-PNP is bound to CCT the substrates move within the chaperonin's cavity. It also seems that in the case of actin, the CAP protein is required as a possible cofactor in actin's final folding states. The exact manner by which this process is regulated is still not fully understood, but it is known that the protein PhLP3 (a protein similar to phosducin) inhibits its activity through the formation of a tertiary complex.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.